| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Viking Global · Andreas Halvorsen | $643.4M | 1.83% | 29.99M | — | Q2 2026 |
| ARK Investment Management · Cathie Wood | $44.8M | 0.29% | 2.09M | — | Q2 2026 |
| Renaissance Technologies | $6.5M | 0.01% | 302.80K | +26% | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $859.9K | 0.00% | 40.09K | −55% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ADPT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Rubinstein JulianPresident | Sale at price 25.66 - 30.53 per share. | 35.6K | $948.22K |
| Oct 7, 2026 | Rubinstein JulianPresident | Conversion of Exercise of derivative security at price 12.14 per share. | 35.6K | $432.71K |
| Oct 5, 2026 | Bobulsky SusanOfficer | Sale at price 30.00 per share. | 6.4K | $193.32K |
| Oct 4, 2026 | Rubinstein JulianPresident | Sale at price 27.57 - 29.67 per share. | 35.6K | $1.01M |
| Oct 4, 2026 | Rubinstein JulianPresident | Conversion of Exercise of derivative security at price 12.14 per share. | 35.6K | $432.71K |
| Sep 30, 2026 | Lo FrancisOfficer | Sale at price 27.52 - 28.61 per share. | 26.8K | $757.70K |
| Sep 30, 2026 | Lo FrancisOfficer | Conversion of Exercise of derivative security at price 3.99 - 8.46 per share. | 26.8K | $181.56K |
| Sep 14, 2026 | Bobulsky SusanOfficer | Sale at price 27.00 per share. | 1.2K | $32.27K |
| Aug 30, 2026 | Owen Katey EinterzDirector | Stock Gift at price 0.00 per share. | 12.5K | — |
| Aug 25, 2026 | Owen Katey EinterzDirector | Sale at price 26.00 per share. | 9.6K | $249.99K |
| Aug 17, 2026 | Hershberg Robert MDirector | Sale at price 24.39 - 24.41 per share. | 30.7K | $748.21K |
| Aug 17, 2026 | Hershberg Robert MDirector | Conversion of Exercise of derivative security at price 6.32 per share. | 15K | $94.80K |
| Aug 17, 2026 | Robins Chad MChief Executive Officer | Sale at price 24.48 - 25.57 per share. | 600K | $14.88M |
| Aug 17, 2026 | Robins Chad MChief Executive Officer | Conversion of Exercise of derivative security at price 6.55 per share. | 600K | $3.93M |
| Aug 16, 2026 | Neupert Peter MDirector | Sale at price 25.10 - 25.23 per share. | 124.7K | $3.14M |
| Aug 16, 2026 | Neupert Peter MDirector | Conversion of Exercise of derivative security at price 6.32 per share. | 15K | $94.80K |
| Aug 9, 2026 | Bobulsky SusanOfficer | Sale at price 25.00 per share. | 3K | $75.00K |
| Jul 29, 2026 | Bobulsky SusanOfficer | Sale at price 24.00 per share. | 1.3K | $31.18K |
| Jul 20, 2026 | Robins Harlan S.Officer | Sale at price 21.72 - 22.12 per share. | 492.4K | $10.78M |
| Jul 20, 2026 | Robins Harlan S.Officer | Conversion of Exercise of derivative security at price 6.55 per share. | 284.8K | $1.87M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.9 | -13.4 | -13.4 | 1.6 | 7.4 | 41.6 | 5.2 | 10.4 | 16.0 | -10.9 | +58.6% | ||
| 2025 | 29.3 | 6.6 | -10.0 | -0.9 | 29.3 | 22.4 | -12.1 | 28.7 | 13.5 | 16.0 | 13.2 | -17.4 | +170.9% |
| 2024 | -25.1 | 12.0 | -21.9 | -18.4 | 31.7 | 4.9 | 25.7 | 3.3 | 8.9 | -5.5 | 22.7 | 0.9 | +22.3% |
| 2023 | 21.3 | -7.8 | 3.3 | -19.1 | -2.5 | -3.6 | 25.8 | -19.8 | -19.5 | -18.5 | -1.4 | 11.9 | −35.9% |
| 2022 | -37.8 | -17.3 | -3.8 | -40.6 | -5.2 | 3.5 | 13.2 | -2.6 | -20.2 | 9.3 | 12.9 | -13.0 | −72.8% |
| 2021 | -6.2 | 2.0 | -28.8 | 3.3 | -9.1 | 8.1 | -10.3 | -0.9 | -6.4 | -1.7 | -21.9 | 7.6 | −52.5% |
| 2020 | -0.1 | -6.0 | -1.1 | 15.2 | 20.9 | 25.0 | -22.9 | 11.5 | 16.9 | -5.2 | 4.6 | 22.6 | +97.6% |
| 2019 | -20.2 | 31.9 | -39.2 | -15.6 | 4.3 | 10.0 | −38.1% |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Buy / hold / sell counts